Literature DB >> 9197561

Tumour cell proliferation after failed ruthenium plaque radiotherapy for posterior uveal melanoma.

S Seregard1, G Lundell, I Lax, E af Trampe, E Kock.   

Abstract

Enucleation following ruthenium plaque radiotherapy for posterior uveal melanoma indicates failure of treatment. This study focused on the histopathological findings and remaining tumour cell growth fraction in 42 of 46 patients with failed ruthenium plaque treatment (of 266 patients treated) for melanoma of the choroid or ciliary body. The cause for enucleation was clinically detected tumour regrowth in 27 (64%) patients, treatment-related ocular side effects in 12 (29%) cases and the patient's personal preference in three (7%) cases. The median time elapsing from plaque radiotherapy to enucleation was not significantly different for patients with recurrent tumour growth (23 months) compared to those enucleated without clinical signs of regrowth (19 months). While all tumours showed some regressive features by histopathological examination, only five melanomas were completely necrotic and viable-appearing tumours cells were present in all of the remaining 37 (88%) irradiated tumours. Microwave processed PC-10 immunostainings increased the sensitivity to detect cycling cells compared to the sole use of mitotic cell counts. By the former technique, proliferating tumour cells were detected in 17 of 23 (74%) studied melanomas of eyes enucleated for tumour regrowth following brachytherapy. Also, the number of cycling melanoma cells was similar to that of non-irradiated controls managed solely by enucleation. In contrast, the proliferative compartments of irradiated, but non-recurrent, posterior uveal melanomas were significantly reduced compared to those of matched controls. Still, cycling tumour cells were present in four of 13 (31%) irradiated melanomas, clinically assumed to be successfully treated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197561     DOI: 10.1111/j.1600-0420.1997.tb00112.x

Source DB:  PubMed          Journal:  Acta Ophthalmol Scand        ISSN: 1395-3907


  5 in total

1.  Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas.

Authors:  C Chiquet; J D Grange; L Ayzac; P Chauvel; L M Patricot; M Devouassoux-Shisheboran
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma.

Authors:  R van Ginderdeuren; E van Limbergen; W Spileers
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  Cell proliferation activity in posterior uveal melanoma after Ru-106 brachytherapy: an EORTC ocular oncology group study.

Authors:  J Pe'er; F H Stefani; S Seregard; T Kivela; P Lommatzsch; J U Prause; B Sobottka; B Damato; I Chowers
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

4.  Cyclooxygenase-2 expression in human irradiated uveal melanomas.

Authors:  Pinar C Ozdal; Sonia Callejo; Amanda L Caissie; Chaim Edelstein; Silvin Bakalian; Raul N G Vianna; Miguel N Burnier
Journal:  Int Ophthalmol       Date:  2007-06-30       Impact factor: 2.031

Review 5.  Uveal melanoma: estimating prognosis.

Authors:  Swathi Kaliki; Carol L Shields; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.